g6 pro Search Results


unblinded dexcom g6  (Dexcom Inc)
86
Dexcom Inc unblinded dexcom g6
Study design overview. Participants were first screened, randomized, and trained in CGM use. Subjects were then assigned to begin with either a <t>10-day</t> <t>unblinded</t> CGM (Dexcom <t>G6)</t> or 10-day blinded CGM (Dexcom G6 Pro) period. Each monitoring phase was followed by completion of the Hypoglycemia Fear Survey-II (HFS-II), an event diary, and training (if applicable) with a new CGM device. All participants crossed over to the alternate CGM modality for another 10-day period. The study concluded with repeated HFS-II assessments, event diary entries, and CGM data download. Blinded CGM data (Dexcom G6 Pro) was used for all outcome analyses to ensure consistency.
Unblinded Dexcom G6, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/g6+pro/dexcom+g6+pro+%E2%80%A2/pmc12371835-104-36-37
Average 86 stars, based on 1 article reviews
unblinded dexcom g6 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Study design overview. Participants were first screened, randomized, and trained in CGM use. Subjects were then assigned to begin with either a 10-day unblinded CGM (Dexcom G6) or 10-day blinded CGM (Dexcom G6 Pro) period. Each monitoring phase was followed by completion of the Hypoglycemia Fear Survey-II (HFS-II), an event diary, and training (if applicable) with a new CGM device. All participants crossed over to the alternate CGM modality for another 10-day period. The study concluded with repeated HFS-II assessments, event diary entries, and CGM data download. Blinded CGM data (Dexcom G6 Pro) was used for all outcome analyses to ensure consistency.

Journal: Journal of the Endocrine Society

Article Title: Continuous Glucose Monitoring in Patients With Postbariatric Hypoglycemia: Effect on Hypoglycemia and Quality of Life

doi: 10.1210/jendso/bvaf106

Figure Lengend Snippet: Study design overview. Participants were first screened, randomized, and trained in CGM use. Subjects were then assigned to begin with either a 10-day unblinded CGM (Dexcom G6) or 10-day blinded CGM (Dexcom G6 Pro) period. Each monitoring phase was followed by completion of the Hypoglycemia Fear Survey-II (HFS-II), an event diary, and training (if applicable) with a new CGM device. All participants crossed over to the alternate CGM modality for another 10-day period. The study concluded with repeated HFS-II assessments, event diary entries, and CGM data download. Blinded CGM data (Dexcom G6 Pro) was used for all outcome analyses to ensure consistency.

Article Snippet: Patients with confirmed PBH were screened for eligibility and if enrolled, were assigned to 2 treatment periods given sequentially but in random order to avoid confounding by treatment order: (1) a 10-day period with use of unblinded Dexcom G6 (the intervention of interest) and (2) a 10-day control period without use of unblinded Dexcom G6 ( ).

Techniques: